Pituitary Tumor Statistics in the US 2026 | Incidence, Types, Symptoms & Key Facts

More than 15,000 pituitary tumors are diagnosed each year in the United States, and imaging studies suggest as many as 1 in 4 people may carry one without ever knowing it. Almost all of these tumors are benign adenomas, with pituitary cancer remaining exceptionally rare at fewer than 1 in 10,000 cases.

Pituitary Tumor in the US 2026 – Introduction

Pituitary tumor reveal one of the more paradoxical corners of American cancer and endocrine data: a tumor type that is, by some measures, among the most common intracranial growths a person can develop, yet remains largely invisible in public health conversations because the overwhelming majority never cause symptoms at all. The American Cancer Society estimates more than 15,000 pituitary tumors are diagnosed annually across the country, a figure that itself represents only the visible tip of a much larger iceberg, since autopsy and imaging studies suggest up to 1 in 4 people may harbor a small pituitary adenoma they will never know about.

This report breaks down pituitary tumor statistics in the US in 2026 across every dimension the current medical literature covers: incidence and prevalence trends, the sharp distinction between benign adenomas and the vanishingly rare pituitary carcinomas, the major hormone-based tumor subtypes and their distinct symptom patterns, demographic disparities by age, sex, and race, treatment and surgical remission rates, and how pituitary tumors compare to other brain and endocrine cancers Americans face. Because so much of the pituitary tumor burden remains undetected and asymptomatic, understanding these numbers requires holding two facts simultaneously: this is both a rare cause of clinical illness and, in raw biological terms, a remarkably common human condition.

Interesting Facts About Pituitary Tumors in the US in 2026

Data Source: American Cancer Society, American Brain Tumor Association, SEER Database (National Cancer Institute)

The numbers above capture a condition whose true scope depends heavily on how you define “having” a pituitary tumor. Using the strictest clinical standard, roughly 1 in 1,000 people carry a pituitary adenoma significant enough to warrant medical attention, translating into the more than 15,000 new diagnoses recorded annually across the United States. Cast the net wider to include every small, silent growth ever detected on autopsy or incidental imaging, and the estimated prevalence balloons to as high as 1 in 4 people, a gap between clinical significance and biological presence rarely seen at this scale in any other tumor type.

What makes pituitary tumors especially reassuring, on balance, is how rarely they turn cancerous. Pituitary carcinomas, the true malignant form capable of spreading beyond the gland itself, occur in fewer than 1 in 10,000 pituitary tumor cases, an annual incidence of just 0.046 per 100,000 people nationally. That extreme rarity stands in sharp contrast to the tumor type’s overall frequency, accounting for roughly 17% of all primary central nervous system tumors and representing the second most common endocrine system tumor in the country, trailing only thyroid tumors in overall frequency.

Pituitary Tumor Incidence and New Diagnoses in 2026

Pituitary Tumor Incidence Rate Trend (SEER Data)
2004 |███████████████ 3.15 per 100,000
2011 |██████████████████████ 4.66 per 100,000
2015 |████████████████████████ Peak year (SEER 2004-2016 study)
2026 |███████████████████████ 4.8 per 100,000 (standardized rate)

Data Source: SEER Database, National Cancer Institute, Scientific Reports (2021)

Pituitary tumor incidence in the United States has climbed steadily for the past two decades, though researchers largely attribute this rise to better detection rather than a true increase in how often these tumors form. A SEER database analysis covering 2004 through 2016 found the age-adjusted incidence rate rose from 3.15 per 100,000 person-years in 2004 to 4.66 per 100,000 by 2011, an annual increase of 5.51%, with incidence continuing to trend upward through a peak observed in 2015. Over that same study window, researchers identified 47,180 total pituitary tumors, the vast majority of which, 47,030 cases, were typical benign adenomas.

Medical researchers consistently point to the same explanation for this rising trend: the increasing availability and use of magnetic resonance imaging. As MRI scans became more routine for evaluating headaches, vision changes, and other unrelated neurological complaints, physicians began incidentally discovering far more pituitary abnormalities than earlier generations of clinicians using less sensitive imaging technology could ever have detected. This detection-driven pattern means the standardized national incidence rate of 4.8 per 100,000 person-years likely reflects improved diagnostic capability at least as much as it reflects any genuine biological increase in tumor formation across the population.

Pituitary Tumor Prevalence: The Hidden Epidemic in 2026

Pituitary Tumor Prevalence by Detection Method
Clinically Diagnosed Adenomas   |███ ~0.1% (1 in 1,000)
Autopsy/Imaging Studies         |████████████████████████ Up to 25% (1 in 4)

Data Source: PubMed Epidemiology Review, American Cancer Society, Global Statistics on Pituitary Tumor

The gap between clinically diagnosed pituitary tumor prevalence and the tumors’ true biological presence in the population represents one of the most striking findings in this entire field of study. While formally diagnosed, clinically relevant pituitary adenomas affect roughly 1 in 1,000 people, studies examining autopsy results and incidental imaging findings, meaning cases discovered while scanning for something entirely unrelated, have found prevalence rates ranging from 10% to as high as 22-25% of the general population, with one comprehensive estimate placing overall prevalence at 16.7%.

This enormous gap exists because the vast majority of small pituitary tumors, known as microadenomas when under 10 millimeters in diameter, never grow large enough or produce enough excess hormone to cause any noticeable symptoms during a person’s lifetime. Many people who die of entirely unrelated causes are found on autopsy to have carried one of these silent growths for years or even decades without ever experiencing a single symptom or requiring any treatment. This reality shapes how endocrinologists counsel patients: an incidentally discovered small pituitary lesion on an unrelated brain scan is, statistically, far more likely to represent one of these common, harmless microadenomas than a tumor requiring aggressive intervention.

Pituitary Adenoma vs. Pituitary Carcinoma in 2026

Pituitary Tumor Malignancy Comparison
Benign Adenomas      |█████████████████████████████████████████ 99.99%+
Malignant Carcinomas |▏ <0.01% (fewer than 1 in 10,000)

Data Source: National Inpatient Sample (NIS), 1997-2016, ScienceDirect

The distinction between pituitary adenomas and pituitary carcinomas represents perhaps the single most reassuring fact in the entire pituitary tumor landscape. Analysis of the National Inpatient Sample, covering nearly two decades of American hospital discharge data from 1997 to 2016, found an annual national incidence of 2.80 per 100,000 for benign adenomas compared to just 0.046 per 100,000 for true malignant carcinomas, a ratio confirming that the overwhelming majority of pituitary tumors carry a fundamentally benign biological behavior regardless of how large they grow or how disruptive their hormonal effects become.

Interestingly, this same research found essentially no meaningful difference in adenoma incidence between sexes, with males recording 2.63 per 100,000 and females 2.78 per 100,000, a gap researchers determined was not statistically significant. However, the study did identify a notable trend specifically within the rare carcinoma category: pituitary carcinoma incidence has been declining over time, but only among female patients and higher-income patients specifically, a pattern researchers suggest may reflect underlying healthcare access disparities or hormone-related biological factors that vary systematically along socioeconomic lines, an area the study’s authors flagged as deserving further investigation.

Pituitary Tumor Types by Hormone Function in 2026

Functional Pituitary Tumor Subtypes (Share of Functional Tumors)
Prolactinoma                |████████████████████████████████████████ 40-66%
Growth Hormone (Acromegaly) |███████████████ 15-20%
ACTH (Cushing's Disease)    |█████████ 10-15%
Thyrotropinoma              |█ ~1%

Data Source: NCBI Endotext, StatPearls, ClinicalTrials.gov Documentation

Pituitary tumors are classified according to which specific hormone-producing cell type they arise from, and this classification directly determines both a patient’s symptoms and their treatment path. Prolactinomas are by far the most common functional subtype, accounting for anywhere from 40% to 66% of all hormone-secreting pituitary tumors depending on the study population, with an estimated incidence of 35 to 50 cases per 100,000 people and a strong tendency to appear in women between ages 20 and 50. Growth hormone-secreting tumors, which cause the condition acromegaly, represent roughly 15% to 20% of functional tumors, while ACTH-secreting corticotroph adenomas, responsible for Cushing’s disease, account for another 10% to 15%.

Beyond these functioning tumor types that actively pump excess hormone into the bloodstream, non-functioning adenomas make up roughly 30% to 35% of all pituitary adenomas overall. Despite producing no hormonal excess whatsoever, these silent tumors represent the great majority of patients who ultimately undergo surgery, precisely because they tend to grow undetected until they become large enough to physically compress surrounding brain structures, at which point the risk of sudden hemorrhage into the tumor, a dangerous complication called pituitary apoplexy, along with progressive vision loss, forces clinical intervention that a purely hormone-driven tumor might have prompted much earlier through its more obvious symptoms.

Pituitary Tumor Symptoms in 2026

Symptom Categories by Tumor Mechanism
Mass Effect Symptoms      |████████████████████████████████ Headaches, vision loss, hypopituitarism
Hormone Excess Symptoms   |████████████████████████████████████████ Varies by tumor subtype

Data Source: NCBI Endotext, Surgical Treatment of Pituitary Adenomas Review

Pituitary tumor symptoms fall into two fundamentally different categories depending on how the tumor affects the body: physical mass effect from the growing tumor itself, and hormonal disruption from whatever specific hormone the tumor cells happen to produce in excess. Mass effect symptoms, which can occur with any sufficiently large tumor regardless of hormonal activity, typically include headaches, progressive visual field deficits as the tumor compresses the optic chiasm sitting directly above the pituitary gland, and hypopituitarism, a state where the compressed normal gland tissue can no longer produce adequate levels of its own essential hormones.

Hormone-specific symptoms vary dramatically by tumor subtype and often provide the first clinical clue leading to diagnosis. Women with prolactinomas classically present with amenorrhea or irregular menstruation alongside galactorrhea, unexpected breast milk production, while affected men more often experience impotence or infertility, symptoms that can delay diagnosis since they’re less immediately obvious than a woman’s menstrual changes. Patients with Cushing’s disease frequently endure a constellation of fatigue, proximal muscle weakness, osteoporosis, high blood pressure, impaired glucose metabolism, and psychiatric or cognitive disturbances, while those with acromegaly develop gradual, often initially unnoticed soft tissue and bony changes alongside elevated risks of hypertension, cardiac disease, and diabetes.

Pituitary Tumor Demographics: Age, Sex, and Race in 2026

Pituitary Adenoma Incidence Patterns by Demographic
Women (Childbearing Years)    |████████████████████████████████████████ Elevated incidence
African Americans/Hispanics   |███████████████████████████████████ Higher incidence than Caucasians
Ages 60-79                    |████████████████████████████████████████████ Most common age at diagnosis (benign tumors)

Data Source: American Brain Tumor Association, PMC Demographic Differences Study, ScienceDirect Benign Pituitary Tumor Study

Demographic patterns in pituitary tumor incidence reveal consistent disparities across sex, race, and age that researchers have documented across multiple independent data sources. Women are more affected than men overall, particularly during their childbearing years, a pattern driven substantially by the higher prevalence of prolactinomas in this population, while the American Brain Tumor Association specifically notes that incidence rates run higher among African Americans and Hispanics compared to Caucasians, a disparity that persists across the socioeconomic and demographic stratification studies examined throughout this report.

Age patterns add further nuance to this demographic picture. A SEER-based study of benign pituitary tumors found most patients were diagnosed between ages 60 and 79, and researchers observed a bimodal age distribution in women, meaning two distinct peaks in diagnosis age, compared to a single, more gradual unimodal pattern in men. That same research found men tend to be diagnosed with larger tumors on average than women, a gap researchers attribute to diagnostic delay: because certain symptoms in men, such as decreased libido or subtle energy changes, are less immediately alarming or easily attributed to other causes than the menstrual irregularities that often prompt earlier medical evaluation in women, male tumors frequently have more time to grow before detection.

Pituitary Tumor Treatment and Surgical Outcomes in 2026

Surgical Remission Rates by Tumor Type
Microprolactinoma              |██████████████████████████████████████████ 92.3%
Acromegaly Symptom Improvement |███████████████████████████████████████████ 95%
Overall Modern Remission       |████████████████████████████ >60%
Somatotroph Macroadenoma       |██████████████████ 40%

Data Source: NCBI Endotext, Surgical Treatment of Pituitary Adenomas

Pituitary tumor treatment outcomes vary considerably depending on tumor type and size at the time of intervention, but overall success rates remain encouraging across most tumor categories. Among functional tumors, microprolactinomas achieve the highest biochemical remission rate at 92.3% following surgery, the best outcome of any pituitary tumor subtype, while somatotroph macroadenomas, the larger growth hormone-secreting tumors responsible for acromegaly, show the lowest remission rate at just 40%, reflecting how tumor size and the specific hormone-producing cell type both meaningfully affect surgical success.

Acromegaly patients specifically see symptoms improve in 95% of cases following surgical treatment, with recurrence occurring in less than 2% of patients at ten years post-surgery, a durable long-term outcome. Using modern remission criteria, which require normalized IGF-1 levels alongside specific growth hormone suppression thresholds, overall surgical biochemical remission now exceeds 60% across pituitary tumor surgeries broadly. Even so, complete tumor removal remains challenging in a meaningful minority of cases: residual tumor tissue persists in up to 20% of surgical patients, an outcome that typically necessitates either repeat surgery or ongoing medical therapy to manage the remaining disease, particularly in tumors that have invaded surrounding structures like the cavernous sinus, where curative surgical removal becomes far more technically difficult.

Pituitary Tumors Compared to Other Brain and Endocrine Tumors in 2026

Annual New Cases: Pituitary vs. Other Brain/Endocrine Tumors (US)
Thyroid Cancer           |████████████████████████████████████████████████ 45,240
Pituitary Tumors         |████████████████ 15,000+
Brain Cancer (Malignant) |████████████████████████ 24,820

Data Source: American Cancer Society, CBTRUS Statistical Report

Placing pituitary tumors alongside other tumors affecting the brain and endocrine system helps clarify where this condition fits within America’s broader tumor landscape. Thyroid cancer, detailed extensively in the Thyroid Cancer Statistics in US report, remains the more common endocrine malignancy overall, with an estimated 45,240 new cases projected for 2026, roughly three times the pituitary tumor diagnosis count, though thyroid cancer carries a genuine malignancy risk that pituitary tumors almost never do. Among primary brain tumors more broadly, detailed in the Brain Cancer Statistics in US report’s figure of 24,820 new malignant brain cancer cases projected for 2025, pituitary tumors account for a meaningful share of overall intracranial tumor diagnoses despite their near-universally benign nature.

This comparison highlights the central paradox running through pituitary tumor statistics: despite being classified among primary central nervous system tumors and representing roughly 17% of that broader category, pituitary tumors behave nothing like the aggressive malignant brain cancers, such as glioblastoma, that dominate public perception of what a “brain tumor” diagnosis means. Where malignant brain tumors carry mortality rates that make them among the most feared cancer diagnoses, the vast majority of pituitary tumor patients face a fundamentally different clinical reality: a benign, treatable condition where the primary challenge lies in managing hormonal symptoms or mass effect rather than fighting a life-threatening malignancy.

Pituitary Tumor Survival and Broader Cancer Context in 2026

Pituitary Tumors Within the Broader US Cancer Landscape
Total New US Cancer Cases (2025)     |████████████████████████████████████████ 2,041,910
Pituitary Tumors as Share of Total   |▏ <1%

Data Source: SEER Database, National Cancer Institute

Within the full sweep of American cancer statistics, detailed comprehensively in the Cancer Statistics in the US report’s finding that 2,041,910 new cancer cases were projected for 2025 alone, pituitary tumors represent a genuinely small slice of the nation’s overall tumor burden, and their near-uniformly benign nature means they contribute minimally to cancer mortality statistics compared to the roughly 10.3% of American adults who carry a lifetime cancer diagnosis of any type. A SEER-based analysis of benign pituitary tumor patients found 89.07% survived through the study’s follow-up period, with typical adenoma classification, younger age at diagnosis, and smaller tumor size all independently associated with improved long-term survival outcomes.

This favorable survival profile stands in sharp contrast to many of the malignant cancers that dominate national cancer statistics and public health attention, underscoring why pituitary tumors, despite their surprising frequency once incidental and autopsy-detected cases are included, rarely feature prominently in broader cancer awareness campaigns or public health messaging. The same research identified that Black patients and male patients experienced somewhat worse overall survival even among this generally benign tumor category, a demographic disparity that echoes patterns seen across other tumor types studied throughout the American cancer literature and suggests healthcare access and treatment timing may meaningfully influence outcomes even for conditions with an otherwise excellent overall prognosis.

Pituitary Tumor – Frequently Asked Questions

How common are pituitary tumors in the US? More than 15,000 pituitary tumors are diagnosed annually in the United States, though studies suggest as many as 1 in 4 people may have a small, undetected pituitary adenoma at some point in their life.

Are pituitary tumors cancerous? Almost never. Pituitary carcinomas, the true malignant form, occur in fewer than 1 in 10,000 pituitary tumor cases; the vast majority are benign adenomas.

What is the most common type of pituitary tumor? Prolactinomas are the most common functional pituitary tumor type, accounting for 40% to 66% of all hormone-secreting pituitary tumors.

What are the symptoms of a pituitary tumor? Symptoms depend on the tumor type and can include headaches, vision loss, and hypopituitarism from mass effect, or hormone-specific symptoms like irregular menstruation and galactorrhea from prolactinomas, or fatigue and weight changes from Cushing’s disease.

Who is most at risk for pituitary tumors? Women, particularly during childbearing years, and African American and Hispanic populations show higher incidence rates compared to Caucasian populations, according to the American Brain Tumor Association.

What is the survival rate for pituitary tumors? Survival is generally excellent given the tumors’ predominantly benign nature; one SEER-based study found 89.07% of patients survived through the study’s follow-up period.

How are pituitary tumors treated? Treatment depends on tumor type and size, ranging from dopamine agonist medications for prolactinomas to transsphenoidal surgery for most other tumor types, with overall biochemical remission rates now exceeding 60% using modern surgical criteria.

What is the difference between a microadenoma and a macroadenoma? Microadenomas are smaller than 10 millimeters and often cause no symptoms, while macroadenomas exceed 10 millimeters and are more likely to cause vision problems or hormone deficiencies from compressing surrounding structures.

How does a pituitary tumor compare to other brain tumors? Pituitary tumors account for roughly 17% of all primary central nervous system tumors but behave very differently from malignant brain cancers like glioblastoma, since the vast majority are benign and highly treatable.

Can a pituitary tumor go undetected for years? Yes. Because many pituitary tumors are small and produce no symptoms, autopsy and imaging studies suggest a large share of the population carries one without ever being diagnosed during their lifetime.

Disclaimer: This research report is compiled from publicly available American Cancer Society, National Cancer Institute SEER Program, and peer-reviewed medical literature sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty is given as to the completeness or reliability of the information presented. This report is for informational purposes only and does not constitute medical advice; anyone with symptoms or concerns about a pituitary condition should consult a licensed healthcare provider.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE